FDA approves secnidazole for treatment of trichomoniasis in adults
The U.S Food and drug administration (FDA) has approved an expanded indication for SOLOSEC (secnidazole) to include the treatment of trichomoniasis in adults patients and their partners. The drug has already been approved in 2017 for bacterial vaginosis (BV) in adult women.
The approval has been granted toLupin Pharmaceuticals, Inc.
SOLOSEC® is now the only single-dose oral prescription antimicrobial agent approved for the treatment of both BV and trichomoniasis in the U.S. Having a treatment option for patients with both of these infectious diseases that provides a complete course of therapy in a single dose will help address gaps in care related to adherence, and therefore, may reduce risk factors associated with trichomoniasis or BV, such as pelvic inflammatory disease (PID) and other STIs.
The approval was based on a landmark Phase 3 clinical trial which demonstrated a 92.2% clinically and statistically significant cure rate for patients with Trichomoniasis – the most common non-viral, curable sexually transmitted infection in the U.S., affecting an estimated 3-5 million Americans every year.The data were recently published in Clinical Infectious Diseases in March 2021 and presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.